Immunovant, Inc. (IMVT) stock
IMVTNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends March 31
$33.21−0.07 (-0.21%)
Close on Nov 17, 2026Market cap $6.86BP/E –Yield –
Immunovant market cap
Market capitalization is the share price multiplied by the number of shares outstanding.
Immunovant's market cap was $7.64B on Nov 11, 2026, against $4.21B a year earlier. Over the last 5 years it ranged from $454.28M to $8.42B, with a median of $3.63B.
Market Cap at the end of each year
| Period | Period end | Value | Change |
|---|---|---|---|
| 2026 | Nov 11, 2026 | $7.64B | +72.2% |
| 2025 | Dec 31, 2025 | $4.44B | +22.2% |
| 2024 | Dec 31, 2024 | $3.63B | -34.4% |
| 2023 | Dec 29, 2023 | $5.54B | +167.5% |
| 2022 | Dec 30, 2022 | $2.07B | +111.3% |
| 2021 | Dec 31, 2021 | $979.79M | -78.3% |
| 2020 | Dec 31, 2020 | $4.52B | +2319.6% |
| 2019 | Dec 31, 2019 | $186.87M | – |
See a number that looks wrong?